Free Trial

Blueprint Medicines Q4 2023 Earnings Report

Blueprint Medicines logo
$90.14 +1.21 (+1.36%)
(As of 12/20/2024 05:31 PM ET)

Blueprint Medicines EPS Results

Actual EPS
-$1.82
Consensus EPS
-$2.04
Beat/Miss
Beat by +$0.22
One Year Ago EPS
-$2.65

Blueprint Medicines Revenue Results

Actual Revenue
$71.96 million
Expected Revenue
$67.34 million
Beat/Miss
Beat by +$4.62 million
YoY Revenue Growth
+85.50%

Blueprint Medicines Announcement Details

Quarter
Q4 2023
Time
Before Market Opens

Conference Call Resources

70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here << 

Blueprint Medicines Earnings Headlines

Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
J.P. Morgan’s top Healthcare stocks for 2025
See More Blueprint Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Blueprint Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Blueprint Medicines and other key companies, straight to your email.

About Blueprint Medicines

Blueprint Medicines (NASDAQ:BPMC), a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

View Blueprint Medicines Profile

More Earnings Resources from MarketBeat

Upcoming Earnings